



# Test Catalog

Diagnostic. Prognostic. Predictive. Predisposition.





# Targeted Solid Tumor NGS Fusion Panel

## Alternative Name

Targeted Solid Tumor Fusion Panel

## Methodology

Molecular

## Test Description

The Targeted Solid Tumor NGS Fusion Panel is an RNA-based next-generation sequencing panel that detects translocations and fusions with known and novel fusion partners of these genes: ALK, BRAF, FGFR1, FGFR2, FGFR3, FGFR4, MET including MET Exon 14 skipping, NOTCH1, NOTCH2, NRG1, NTRK1, NTRK2, NTRK3, PDGFB, PDGFRA, PDGFRB, RAF1, RET, and ROS1.

## Clinical Significance

Gene fusion events that deregulate protein expression or generate a chimeric protein are associated with the pathology of several cancer types. The Targeted Solid Tumor NGS Fusion Panel is intended to identify gene fusions that have been reported as oncogenic drivers in multiple solid tumors, including but not limited to NSCLC, urothelial carcinoma, cholangiocarcinoma, and thyroid carcinoma. Patients with the gene fusions may respond to select kinase inhibitors that have been approved by the FDA, including crizotinib, ceritinib, imatinib, larotrectinib, entrectinib, pemigatinib, and selpercatinib.

## Specimen Requirements

- **FFPE tissue:** Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.

## Storage & Transportation

Use cold pack for transport, making sure cold pack is not in direct contact with specimen.

## CPT Code(s)\*

81449

## Medicare MoIDX CPT Code(s)\*

81449

## New York Approved

Yes

## Level of Service

Global

## Turnaround Time

21 Days

\*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.

NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-certified laboratories.

Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information.

\*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.



9490 NeoGenomics Way  
Fort Myers, FL 33912  
Phone: 239.768.0600/ Fax: 239.690.4237  
neogenomics.com  
© 2023 NeoGenomics Laboratories, Inc. All Rights Reserved.  
All other trademarks are the property of their respective owners  
Rev. 040223